Compare Stocks: MIRA, RFL, VTVT, and VANI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIRA MIRA Pharmaceuticals	$0.75 -2.7%	$0.81	$0.60 ▼ $2.45	$32.52M	1.52	1.59 million shs	171,490 shs
RFL Rafael	$2.20 -3.5%	$2.21	$1.12 ▼ $3.96	$118.56M	0.4	119,765 shs	57,376 shs
VANI Vivani Medical	$1.26 -0.8%	$1.38	$0.92 ▼ $1.92	$114.56M	2.36	241,177 shs	150,521 shs
VTVT vTv Therapeutics	$31.44 -1.7%	$32.63	$18.97 ▼ $44.00	$125.93M	0.29	45,572 shs	22,151 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIRA MIRA Pharmaceuticals	-2.74%	-1.47%	-3.54%	-20.78%	-48.10%
RFL Rafael	-4.56%	-15.38%	+9.62%	-14.20%	+62.96%
VANI Vivani Medical	-0.79%	-15.44%	-10.00%	+7.69%	+4.13%
VTVT vTv Therapeutics	-1.66%	-5.73%	+4.38%	-2.48%	+58.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIRA MIRA Pharmaceuticals	$0.75 -2.7%	$0.81	$0.60 ▼ $2.45	$32.52M	1.52	1.59 million shs	171,490 shs
RFL Rafael	$2.20 -3.5%	$2.21	$1.12 ▼ $3.96	$118.56M	0.4	119,765 shs	57,376 shs
VANI Vivani Medical	$1.26 -0.8%	$1.38	$0.92 ▼ $1.92	$114.56M	2.36	241,177 shs	150,521 shs
VTVT vTv Therapeutics	$31.44 -1.7%	$32.63	$18.97 ▼ $44.00	$125.93M	0.29	45,572 shs	22,151 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIRA MIRA Pharmaceuticals	-2.74%	-1.47%	-3.54%	-20.78%	-48.10%
RFL Rafael	-4.56%	-15.38%	+9.62%	-14.20%	+62.96%
VANI Vivani Medical	-0.79%	-15.44%	-10.00%	+7.69%	+4.13%
VTVT vTv Therapeutics	-1.66%	-5.73%	+4.38%	-2.48%	+58.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MIRA MIRA Pharmaceuticals	2.00	Hold	N/A	N/A
RFL Rafael	1.00	Sell	N/A	N/A
VANI Vivani Medical	2.25	Hold	$3.75	197.62% Upside
VTVT vTv Therapeutics	2.78	Moderate Buy	$55.83	77.59% Upside

Current Analyst Ratings Breakdown

Latest MIRA, RFL, VTVT, and VANI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/2/2026	VTVT vTv Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/25/2026	RFL Rafael	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/20/2026	MIRA MIRA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	VTVT vTv Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
8/7/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/6/2026	MIRA MIRA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/6/2026	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$45.00 ➝ $42.00
7/16/2026	VTVT vTv Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$49.00 ➝ $57.00
7/7/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/30/2026	VTVT vTv Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$67.00

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.25 per share	N/A
RFL Rafael	$920K	124.35	N/A	N/A	$1.91 per share	1.15
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.20 per share	N/A
VTVT vTv Therapeutics	$1.02M	121.44	N/A	N/A	$16.36 per share	1.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MIRA MIRA Pharmaceuticals	-$10.44M	-$1.24	N/A	N/A	N/A	N/A	-106.95%	-104.18%	12/2/2026 (Estimated)
RFL Rafael	-$30.52M	-$0.68	N/A	N/A	N/A	-3,321.74%	-41.27%	-35.32%	10/28/2026 (Estimated)
VANI Vivani Medical	-$26.61M	-$0.35	N/A	N/A	N/A	N/A	-191.05%	-70.91%	11/12/2026 (Estimated)
VTVT vTv Therapeutics	-$26.97M	-$1.06	N/A	N/A	N/A	N/A	-6.27%	-5.06%	11/5/2026 (Estimated)

Latest MIRA, RFL, VTVT, and VANI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	VANI Vivani Medical	-$0.0833	-$0.07	+$0.0133	-$0.07	N/A	N/A
8/12/2026	Q2 2026	MIRA MIRA Pharmaceuticals	N/A	-$0.03	N/A	-$0.03	N/A	N/A
8/6/2026	Q2 2026	VTVT vTv Therapeutics	-$0.97	-$1.05	-$0.08	-$1.05	$0.33 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RFL Rafael	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MIRA MIRA Pharmaceuticals	N/A	200.08	200.08
RFL Rafael	N/A	3.16	3.14
VANI Vivani Medical	N/A	3.25	3.25
VTVT vTv Therapeutics	N/A	12.48	12.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MIRA MIRA Pharmaceuticals	35.16%
RFL Rafael	11.30%
VANI Vivani Medical	6.78%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
MIRA MIRA Pharmaceuticals	19.89%
RFL Rafael	32.90%
VANI Vivani Medical	53.30%
VTVT vTv Therapeutics	5.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MIRA MIRA Pharmaceuticals	2	42.02 million	33.66 million	Not Optionable
RFL Rafael	20	52.00 million	34.89 million	Optionable
VANI Vivani Medical	20	90.20 million	42.13 million	Optionable
VTVT vTv Therapeutics	9	3.94 million	3.70 million	Not Optionable

MIRA, RFL, VTVT, and VANI Headlines

Recent News About These Companies

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 12 at 6:28 AM | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Raised to Hold at Zacks Research

September 9, 2026 | marketbeat.com

Lifesci Capital Upgrades vTv Therapeutics (NASDAQ:VTVT) to Strong-Buy

September 4, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)

September 3, 2026 | theglobeandmail.com

vTv Therapeutics to Participate in September Investor Conferences

September 2, 2026 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below 50-Day Moving Average - Should You Sell?

September 2, 2026 | marketbeat.com

vTv Therapeutics Inc. Cl A

August 30, 2026 | barrons.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 19, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts

August 18, 2026 | marketbeat.com

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2026 | markets.businessinsider.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 28, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 2, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next

May 17, 2026 | finance.yahoo.com

Why vTv Therapeutics Inc.’s (VTVT) Stock Is Down 8.13%

May 16, 2026 | aaii.comA

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

May 15, 2026 | zacks.com

vTv Therapeutics Expands At-The-Market Share Program Capacity

May 13, 2026 | tipranks.com

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 8, 2026 | globenewswire.com

vTv Therapeutics to Participate in Upcoming May Investor Conferences

May 7, 2026 | globenewswire.com

Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?

April 20, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA, RFL, VTVT, and VANI Company Descriptions

MIRA Pharmaceuticals NASDAQ:MIRA

$0.75 -0.02 (-2.74%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$0.76 +0.01 (+0.72%)

As of 09/14/2026 07:49 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Rafael NYSE:RFL

$2.20 -0.08 (-3.51%)

Closing price 09/14/2026 03:58 PM Eastern

Extended Trading

$2.25 +0.05 (+2.27%)

As of 09/14/2026 07:30 PM Eastern

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Vivani Medical NASDAQ:VANI

$1.26 -0.01 (-0.79%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$1.25 -0.01 (-0.40%)

As of 09/14/2026 07:30 PM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

vTv Therapeutics NASDAQ:VTVT

$31.44 -0.53 (-1.66%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$31.52 +0.07 (+0.24%)

As of 09/14/2026 07:30 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MIRA, RFL, VTVT, and VANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MIRA, RFL, VTVT, and VANI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MIRA, RFL, VTVT, and VANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA, RFL, VTVT, and VANI Company Descriptions

MIRA Pharmaceuticals NASDAQ:MIRA

Rafael NYSE:RFL

Vivani Medical NASDAQ:VANI

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MIRA, RFL, VTVT, and VANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MIRA, RFL, VTVT, and VANI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MIRA, RFL, VTVT, and VANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA, RFL, VTVT, and VANI Company Descriptions

MIRA Pharmaceuticals NASDAQ:MIRA

Rafael NYSE:RFL

Vivani Medical NASDAQ:VANI

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools